keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung cancer

keyword
https://www.readbyqxmd.com/read/28240848/prognostic-significance-of-a-tumor-marker-index-based-on-preoperative-serum-carcinoembryonic-antigen-and-krebs-von-den-lungen-6-levels-in-non-small-cell-lung-cancer
#1
Masaki Tomita, Takanori Ayabe, Eiichi Chosa, Naohiro Nose, Kunihide Nakamura
Background: We retrospectively analysed the prognostic significance of a tumor marker index (TMI) based on preoperative serum carcinoembryonic antigen (CEA) and Krebs von den Lungen-6 (KL-6) levels in nonsmall cell lung cancer (NSCLC) patients. Materials and Methods: We enrolled 176 NSCLC patients who had preoperative serum CEA and KL-6 level measurements and had undergone curative surgery between 2009 and 2011. Results: The 5-year disease-specific survival of patients with high serum CEA levels was significantly poorer compared with that of patients with normal levels...
1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28240528/novel-mutations-of-the-chrna3-gene-in-non-small-cell-lung-cancer-in-an-iranian-population
#2
Nahid Mehrabi, Seyed Mohammad Moshtaghioun, Hossein Neamatzadeh
Background: Lung cancer, the leading cause of cancer-related worldwide deaths, largely results from the combined effects of smoking exposure and genetic susceptibility. CHRNA3, a nicotinic acetylcholine receptor gene, is associated with lung cancer risk. This study sought to identify variations in exon 3 of CHRNA3 in an Iranian population with non-small cell lung cancer (NSCLC). Materials and methods: A case-control study including 147 individuals with lung cancer and 145 healthy individuals was conducted. As mobility shift caused by nucleotide substitutions might be due to a conformational change of single-stranded DNAs, we designated these as single-strand conformation polymorphisms (SSCPs)...
1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28240169/epigenetic-modulation-using-small-molecules-targeting-histone-acetyltransferases-in-disease
#3
André Richters, Angela N Koehler
Histone acetyltransferases (HATs) are epigenetic drivers that catalyze the acetyl transfer from acetyl-CoA to lysines of both histone and non-histone substrates and thereby induce transcription either by chromatin remodeling or direct transcription factor activation. Histone deacetylases (HDACs) conduct the reverse reaction to counter HAT activity. Physiological processes such as cell cycle progression or apoptosis require a thoroughly balanced equilibrium of the interplay between acetylation and deacetylation processes to maintain or, if required, alter the global acetylome status...
February 23, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28240049/deep-sequencing-of-the-tp53-gene-reveals-a-potential-risk-allele-for-non-small-cell-lung-cancer-and-supports-the-negative-prognostic-value-of-tp53-variants
#4
Christophe Deben, Jolien Van den Bossche, Nele Van Der Steen, Filip Lardon, An Wouters, Ken Op de Beeck, Christophe Hermans, Julie Jacobs, Marc Peeters, Guy Van Camp, Christian Rolfo, Vanessa Deschoolmeester, Patrick Pauwels
The TP53 gene remains the most frequently altered gene in human cancer, of which variants are associated with cancer risk, therapy resistance, and poor prognosis in several tumor types. To determine the true prognostic value of TP53 variants in non-small cell lung cancer, this study conducted further research, particularly focusing on subtype and tumor stage. Therefore, we determined the TP53 status of 97 non-small cell lung cancer adenocarcinoma patients using next generation deep sequencing technology and defined the prognostic value of frequently occurring single nucleotide polymorphisms and mutations in the TP53 gene...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28239820/long-non-coding-rna-neat1-acts-as-oncogene-in-nsclc-by-regulating-the-wnt-signaling-pathway
#5
S-J Sun, Q Lin, J-X Ma, W-W Shi, B Yang, F Li
OBJECTIVE: The present study aimed to explore the role of long non-coding RNA NEAT1 (NEAT1) in mediating non-small cell lung cancer (NSCLC) cell migration and invasion, as well as the underlying regulatory mechanisms. PATIENTS AND METHODS: The NEAT1 expression in NSCLC tissues and cell lines was measured using reverse transcription‑quantitative polymerase chain reaction (RT-qPCR). The relationships between NEAT1 expression and clinicopathological parameters were examined by chi-square test...
February 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28239819/mir-137-and-its-target-tgfa-modulate-cell-growth-and-tumorigenesis-of-non-small-cell-lung-cancer
#6
X Liu, L Chen, X-D Tian, T Zhang
OBJECTIVE: MiR-137 has been reported to serve as a tumor suppressor in non-small cell lung cancer (NSCLC). However, the potential mechanism remains largely unclear. The present study aimed to explore the potential molecular mechanisms by which miR-137 regulated NSCLC. MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to quantify the expression levels of miR-137 in NSCLC tissues and cell lines. Dual-luciferase reporter assay was employed to confirm the specificity of miR-137 target genes...
February 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28239469/combination-immunotherapy-a-road-map
#7
REVIEW
Patrick A Ott, F Stephen Hodi, Howard L Kaufman, Jon M Wigginton, Jedd D Wolchok
Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28239466/nivolumab-induced-myxedema-crisis
#8
Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu, Tarik Hadid
BACKGROUND: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxedema crisis induced by nivolumab in a patient with metastatic squamous cell carcinoma of lung. CASE PRESENTATION: Fifty three-year old woman with metastatic squamous cell carcinoma currently on treatment with nivolumab presented with diffuse facial and tongue swelling, slurred speech, depressed mentation, fatigue and weakness...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28238961/alectinib-for-patients-with-alk-rearrangement-positive-non-small-cell-lung-cancer-and-a-poor-performance-status-lung-oncology-group-in-kyushu-1401
#9
Eiji Iwama, Yasushi Goto, Haruyasu Murakami, Taishi Harada, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, Noriaki Nakagaki, Yuka Fujita, Masahiro Seike, Akihiro Bessho, Manabu Ono, Akihito Okazaki, Hiroaki Akamatsu, Ryotaro Morinaga, Shinichiro Ushijima, Takayuki Shimose, Shoji Tokunaga, Akinobu Hamada, Nobuyuki Yamamoto, Yoichi Nakanishi, Kenji Sugio, Isamu Okamoto
INTRODUCTION: Alectinib has shown marked efficacy and safety in patients with ALK rearrangement-positive non-small cell lung cancer (NSCLC) and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS. METHODS: Eligible patients with advanced ALK rearrangement-positive NSCLC and a PS of 2 to 4 received alectinib orally at 300 mg twice daily. The primary end point of the study was objective response rate (ORR), and the most informative secondary end point was rate of PS improvement...
February 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28238444/pet-ct-in-presurgical-lymph-node-staging-in-non-small-cell-lung-cancer-the-importance-of-false-negative-and-false-positive-findings
#10
A Bustos García de Castro, J Ferreirós Domínguez, R Delgado Bolton, C Fernández Pérez, B Cabeza Martínez, M García García-Esquinas, J L Carreras Delgado
OBJECTIVE: To assess the importance of false-negative and false-positive findings in computed tomography (CT) and (18)F-FDG positron emission tomography (PET) in mediastinal lymph node staging in patients undergoing surgery for non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: This retrospective study included 113 consecutive patients and 120 resected NSCLCs; 22 patients received neoadjuvant treatment. We compared the findings on preoperative (18)F-FDG PET-CT studies with the postoperative pathology findings...
February 23, 2017: Radiología
https://www.readbyqxmd.com/read/28237877/osimertinib-induces-autophagy-and-apoptosis-via-reactive-oxygen-species-generation-in-non-small-cell-lung-cancer-cells
#11
Zheng-Hai Tang, Wen-Xiang Cao, Min-Xia Su, Xiuping Chen, Jin-Jian Lu
Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. Herein, we indicated for the first time that OSI increased the accumulations of cytoplasmic vacuoles, the expression of phosphatidylethanolamine-modified microtubule-associated protein light-chain 3 (LC3-II), and the formation of GFP-LC3 puncta in various cancer cells...
February 22, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28237401/unraveling-biophysical-interactions-of-radiation-pneumonitis-in-non-small-cell-lung-cancer-via-bayesian-network-analysis
#12
Yi Luo, Issam El Naqa, Daniel L McShan, Dipankar Ray, Ines Lohse, Martha M Matuszak, Dawn Owen, Shruti Jolly, Theodore S Lawrence, Feng-Ming Spring Kong, Randall K Ten Haken
BACKGROUND: In non-small-cell lung cancer radiotherapy, radiation pneumonitis≥grade 2 (RP2) depends on patients' dosimetric, clinical, biological and genomic characteristics. METHODS: We developed a Bayesian network (BN) approach to explore its potential for interpreting biophysical signaling pathways influencing RP2 from a heterogeneous dataset including single nucleotide polymorphisms, micro RNAs, cytokines, clinical data, and radiation treatment plans before and during the course of radiotherapy...
February 22, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28237400/individualized-early-death-and-long-term-survival-prediction-after-stereotactic-radiosurgery-for-brain-metastases-of-non-small-cell-lung-cancer-two-externally-validated-nomograms
#13
Jaap D Zindler, Arthur Jochems, Frank J Lagerwaard, Rosemarijne Beumer, Esther G C Troost, Daniëlle B P Eekers, Inge Compter, Peter-Paul van der Toorn, Marion Essers, Bing Oei, Coen W Hurkmans, Anna M E Bruynzeel, Geert Bosmans, Ans Swinnen, Ralph T H Leijenaar, Philippe Lambin
INTRODUCTION: Commonly used clinical models for survival prediction after stereotactic radiosurgery (SRS) for brain metastases (BMs) are limited by the lack of individual risk scores and disproportionate prognostic groups. In this study, two nomograms were developed to overcome these limitations. METHODS: 495 patients with BMs of NSCLC treated with SRS for a limited number of BMs in four Dutch radiation oncology centers were identified and divided in a training cohort (n=214, patients treated in one hospital) and an external validation cohort n=281, patients treated in three other hospitals)...
February 23, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28237354/-crizotinib-for-ros1-rearranged-non-small-cell-lung-cancer-patients
#14
Charlotte Domblides, Martine Antoine, Armelle Lavole, Jacques Cadranel, Marie Wislez
ROS1 fusions are rare mutations that preferentially concern young and non-smoker women. The ROS1-rearranged protein conserves an intact tyrosine kinase domain, leading to the constitutive activation of the ROS1 tyrosine kinase function and of its downstream pathways, that are known to be involved in tumorigenesis. These molecular abnormalities have shown their oncogenic potential in animals' models and in human, with an early effect on carcinogenesis. Several partners have been identified. Patients with non-small cell lung cancers (NSCLC) harbouring ROS1 alterations can received specific targeted therapies...
February 22, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28237293/method-of-predicting-the-mean-lung-dose-based-on-a-patient-s-anatomy-and-dose-volume-histograms
#15
Anna Zawadzka, Marta Nesteruk, Beata Brzozowska, Paweł F Kukołowicz
The aim of this study was to propose a method to predict the minimum achievable mean lung dose (MLD) and corresponding dosimetric parameters for organs-at-risk (OAR) based on individual patient anatomy. For each patient, the dose for 36 equidistant individual multileaf collimator shaped fields in the treatment planning system (TPS) was calculated. Based on these dose matrices, the MLD for each patient was predicted by the homemade DosePredictor software in which the solution of linear equations was implemented...
April 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28237243/non-small-cell-lung-cancer-patients-with-adenocarcinoma-morphology-have-a-better-outcome-compared-with-patients-diagnosed-with-non-small-cell-lung-cancer-favor-adenocarcinoma
#16
Iris Shiran, Eyal Heller, Shlomit Jessel, Iris Kamer, Inbal Daniel-Meshulam, Rossie Navon, Damien Urban, Amir Onn, Jair Bar
BACKGROUND: Non-small-cell lung cancer (NSCLC) includes 2 major histologic subtypes: squamous cell carcinoma and non-squamous carcinoma, mainly adenocarcinoma, a distinction that carries significant clinical and therapeutic implications. NSCLC is diagnosed as adenocarcinoma or as squamous cell carcinoma on the basis of histologic parameters. However, when morphology is inconclusive, tumors with immunohistochemistry (IHC) findings characteristic of adenocarcinoma are referred to as "NSCLC favor adenocarcinoma" (NFA)...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28237242/early-results-of-lung-cancer-screening-and-radiation-dose-assessment-by-low-dose-ct-at-a-community-hospital
#17
Corbin D Jacobs, Mary Ellen Jafari
BACKGROUND: The National Lung Screening Trial showed a reduction in overall and cancer-specific mortality for patients screened with low-dose computed tomography (LDCT) versus chest radiograph. Some question whether this can be achieved in community healthcare settings. Our aim was to analyze lung cancer screening outcomes and administered radiation dose using LDCT scans at a community hospital. PATIENTS AND METHODS: We retrospectively reviewed the records of 680 patients who underwent LDCT between June 2014 and December 2015, and who met Centers for Medicare and Medicaid Services lung cancer screening criteria: asymptomatic, aged 55 to 77 years, smoked within the last 15 years, and ≥ 30 pack-year history...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28237165/treatment-of-choice-for-patients-with-egfr-mutation-positive-non-small-cell-lung-carcinoma-presenting-with-choroidal-metastases-radiotherapy-or-tkis
#18
David Maskell, Konstantinos Geropantas, Michael Kouroupis, Andrew Glenn, Thankamma Ajithkumar
INTRODUCTION: It is not uncommon for patients with non-small cell lung cancer (NSCLC) to develop choroidal metastases (CM). External beam radiotherapy (EBRT) has traditionally been considered the treatment of choice for CM as it offers high response rates and quick relief of symptoms. However, new targeted treatments can offer an effective, alternative treatment strategy for patients harbouring specific genetic abnormalities. CASE STUDY: We present the case of a patient presenting with a symptomatic metastasis to the choroid from an epidermal growth factor receptor (EGFR) mutation-positive NSCLC and exhibiting an excellent clinical and radiological response to the tyrosine kinase inhibitor (TKI) gefitinib...
February 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28236982/prognostic-and-predictive-value-of-loss-of-nuclear-rad51-immunoreactivity-in-resected-non-small-cell-lung-cancer-patients
#19
Mariam Gachechiladze, Josef Škarda, Vítězslav Kolek, Ivona Grygárková, Kateřina Langová, Jan Bouchal, Zdeněk Kolář, Florent Baty, Rolf Stahel, Walter Weder, Alex Soltermann, Markus Joerger
OBJECTIVES: In response to DNA damage, recombination proteins are relocalized into sub-nuclear complexes that are microscopically detected as RAD51-containing nuclear foci. We aimed for assessing the prognostic and predictive value of loss of nuclear RAD51 immunoreactivity ('RAD51 loss') in 2 independent stage I to III non-small cell lung cancer (NSCLC) patient cohorts undergoing surgical resection and eventual perioperative chemo-/radiotherapy (CT/RT). MATERIALS AND METHODS: The discovery set included 69 evaluable patients (19 adenocarcinomas, ADC, 50 squamous cell carcinomas, SCC) from Palacky University Hospital, 45/69 (65...
March 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28236981/phase-i-ii-study-of-tecemotide-as-immunotherapy-in-japanese-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer
#20
Nobuyuki Katakami, Toyoaki Hida, Hiroshi Nokihara, Fumio Imamura, Hiroshi Sakai, Shinji Atagi, Makoto Nishio, Tatsuhiko Kashii, Miyako Satouchi, Christoph Helwig, Morihiro Watanabe, Tomohide Tamura
OBJECTIVES: Unresectable stage III NSCLC (non-small cell lung cancer) confers a poor prognosis and interest is growing in the use of immunotherapy to improve outcomes for patients with this disease. We investigated the safety and efficacy of maintenance tecemotide, a mucin 1 (MUC1)-specific agent that induces T-cell responses to MUC1, versus placebo in Japanese patients with stage III unresectable NSCLC and no disease progression after primary chemoradiotherapy. MATERIALS AND METHODS: Patients aged ≥20 years with unresectable stage III NSCLC, stable disease or clinical response after primary chemoradiotherapy and performance status ≤1, were recruited across 25 centers in Japan...
March 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
8878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"